The Foreign Investment Promotion Board (FIPB) on Monday cleared a proposal by Ahmedabad-based Claris Lifesciences Ltd to sell its global generic injectables business to US-based Baxter International Inc. for Rs4,020 crore ($625 million), a finance ministry official said on condition of anonymity.
Start your deal-making journey now!
Subscribe now to enjoy unlimited access at just $59.
Premium coverage on private equity, venture capital, and startups in Asia.
Exclusive scoops from our reporters in nine key markets.
In-depth interviews with industry leaders shaping the ecosystem.
Already a Subscriber? Log in
Contact us for corporate subscriptions at subs@dealstreetasia.com